Onkologie. 2022:16(6):317-321 | DOI: 10.36290/xon.2022.067

Advances in the treatment of anal squamous cell cancer

Radka Lohynská1, Filip Pazdírek2, Jana Čejková1
1 Onkologická klinika, 1. LF UK a Fakultní Thomayerova nemocnice, Praha
2 Chirurgická klinika, 2. LF UK a Fakultní nemocnice v Motole, Praha

A specialized multidisciplinary team (MDT) plays a crucial role in optimizing the treatment procedure for anal squamous cell cancer (ASCC). Very early stages are treated only with surgery (<5%), more advanced stages with chemoradiotherapy (CHRT). New regimens of radical CHRT and palliative chemotherapy (CHT) and immunotherapy have shown improved survival. Modern techniques of radiotherapy (RT) lead to a significant reduction in the toxicity of the treatment and enable ambulatory administration of the treatment.

Keywords: anal squamous cell cancer, chemotherapy, radiotherapy, targeted treatment, immunotherapy.

Accepted: November 22, 2022; Published: November 22, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lohynská R, Pazdírek F, Čejková J. Advances in the treatment of anal squamous cell cancer. Onkologie. 2022;16(6):317-321. doi: 10.36290/xon.2022.067.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Martini G, Arrichiello G, Borrelli C, et al. How I treat anal squamous cell carcinoma. ESMO Open. 2020;4(Suppl 2):e000711. doi: 10.1136/esmoopen-2020-000711. Go to original source... Go to PubMed...
    2. Sun G, Dong X, Tang X, et al. The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: a meta-analysis. Oncotarget. 2017;9(8):8081-8088. doi: 10.18632/oncotarget.23545. Go to original source... Go to PubMed...
    3. Union for International Cancer Control, TNM Klasifikace zhoubných novotvarů. 8. vydání 2017, česká verze 2018.
    4. Maas M, Tielbeek JAW, Stoker J. Staging of Anal Cancer: Role of MR Imaging. Magn Reson Imaging Clin N Am. 2020;28(1):127-140. doi: 10.1016/j.mric.2019.09.005 Go to original source... Go to PubMed...
    5. Arcadipane F, Silvetti P, Olivero F, et al. Bone Marrow-Sparing IMRT in Anal Cancer Patients Undergoing Concurrent Chemo-Radiation: Results of the First Phase of a Prospective Phase II Trial. Cancers (Basel). 2020;12(11):3306. doi: 10.3390/cancers12113306. Go to original source... Go to PubMed...
    6. Mahmud A, Poon R, Jonker D. PET imaging in anal canal cancer: a systematic review and meta-analysis. Br J Radiol. 2017 Dec;90(1080):20170370. doi: 10.1259/bjr.20170370. Go to original source... Go to PubMed...
    7. Cardenas ML, Spencer CR, Markovina S, et al. Quantitative FDG-PET/CT predicts local recurrence and survival for squamous cell carcinoma of the anus. Adv Radiat Oncol. 2017;2(3):281-287. doi:10.1016/j.adro.2017.04.007. Go to original source... Go to PubMed...
    8. Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86(1):27-33. doi: 10.1016/j.ijrobp.2012.09.023. Go to original source... Go to PubMed...
    9. Rao S, Guren MG, Khan K, et al. ESMO Guidelines Committee. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up*. Ann Oncol. 2021;32(9):1087-1100. doi: 10.1016/j.annonc.2021.06.015. Go to original source... Go to PubMed...
    10. Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys. 2009;74(3):824-830. doi: 10.1016/j.ijrobp.2008.08.070 Go to original source... Go to PubMed...
    11. Ng M, Leong T, Chander S, et al. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1455-1462. doi:10.1016/j.ijrobp.2011.12.058. Go to original source... Go to PubMed...
    12. Muirhead R, Adams RA, Gilbert DC, et al. NATIONAL GUIDANCE FOR IMRT IN ANAL NATIONAL GUIDANCE FOR IMRT IN ANAL CANCER: the CRUK/MRC oxford institute for radiation oncology, Oxford; School of Medicine, Cardiff University, Cardiff; Sussex Cancer Centre, Royal Sussex County Hospital, Brighton; Mount Vernon Hospital, Northwood; University of Leeds, St James Institute of Oncology, Leeds; 2016. http://analimrtguidance.co.uk/nationalanal-imrt-guidance-v4.pdf. Accessed 17 Jan 2021 - National-Guidance-IMRT-Anal-Cancer-V4-Jan17.pdf (analimrtguidance.co.uk).
    13. Dapper H, Schiller K, Münch S, et al. Have we achieved adequate recommendations for target volume definitions in anal cancer? A PET imaging based patterns of failure analysis in the context of established contouring guidelines. BMC Cancer. 2019;19(1):742. doi: 10.1186/s12885-019-5970-0. Go to original source... Go to PubMed...
    14. Palefsky JM, Lee JY, Jay N, et al. ANCHOR Investigators Group. Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. N Engl J Med. 2022;386(24):2273-2282. doi: 10.1056/NEJMoa2201048. Go to original source... Go to PubMed...
    15. Geh I, Gollins S, Renehan A, et al. Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Anal Cancer. Colorectal Dis. 2017;19 Suppl 1:82-97. doi: 10.1111/codi.13709. Go to original source... Go to PubMed...
    16. Arana R, Fléjou JF, Si-Mohamed A, et al. Clinicopathological and virological characteristics of superficially invasive squamous-cell carcinoma of the anus. Colorectal Dis. 2015;17(11):965-72. doi: 10.1111/codi.12951. Go to original source... Go to PubMed...
    17. Yeung R, McConnell Y, Roxin G, et al. One compared with two cycles of mitomycin C in chemoradiotherapy for anal cancer: Analysis of outcomes and toxicity. Current Oncology. 2014;21:449-456. doi.org/10.3747/co.21.1903. Go to original source... Go to PubMed...
    18. White EC, Goldman K, Aleshin A, et al. Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C. Radiother Oncol. 2015;117(2):240-245. doi: 10.1016/j.radonc.2015.08.015. Go to original source... Go to PubMed...
    19. Souza KT, Pereira AA, Araujo RL, et al. Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysis. Ecancermedicalscience. 2016;10:699. doi: 10.3332/ecancer.2016.699. Go to original source... Go to PubMed...
    20. Benson AB 3rd, Arnoletti JP, Bekaii-Saab T, et al. Anal carcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10(4):449-454. DOI: 10.6004/jnccn.212.0046. Go to original source... Go to PubMed...
    21. Glynne-Jones R, Nilsson PJ, Aschele C, et al. ESMO; ESSO; ESTRO. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014;111(3):330-339. doi: 10.1016/j.radonc.2014.04.013. Go to original source... Go to PubMed...
    22. Moureau-Zabotto L, Venderely V, Abromwitz L et al. Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). Dig Liver Dis 2017;49(8):831-840. DOI: 10.1016/j.dld.2017.05.011. Go to original source... Go to PubMed...
    23. Leon O, Guren MG, Radu C, et al. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. Eur J Cancer. 2015;51(18):2740-2746. doi: 10.1016/j.ejca.2015.08.029. Go to original source... Go to PubMed...
    24. Sparano JA, Lee JY, Palefsky J, et al. Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. J Clin Oncol. 2017;35(7):727-733. doi: 10.1200/JCO.2016.69.1642 Go to original source... Go to PubMed...
    25. Vendrely V, Lemanski C, Gnep K, et al; for FFCD investigators/Collaborators. Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904). Radiother Oncol. 2019;140:84-89. doi: 10.1016/j.radonc.2019.05.018. Go to original source... Go to PubMed...
    26. Feliu J, Garcia-Carbonero R, Capdevila J, et al. VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02). Cancer Med. 2020;9(3):1008-1016. doi: 10.1002/cam4.2722. Go to original source... Go to PubMed...
    27. Martin D, Balermpas P, Gollrad J, et al E. RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clin Transl Radiat Oncol. 2020;23:43-49. doi: 10.1016/j.ctro.2020.04.010. Go to original source... Go to PubMed...
    28. Sebag-Montefiore D: The treatment of Anal Cancer; ESTRO kongres, Vídeň, 2020 - PLATO trial: PersonaLising Anal cancer radioTherapy dOse - incorporating ACT3, ACT4 and ACT5. 2020. ISRCTN registry.
    29. Wo JY, Plastaras JP, Metz JM, et al. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study. Int J Radiat Oncol Biol Phys. 2019;105(1):90-95. doi: 10.1016/j.ijrobp.2019.04.040. Go to original source... Go to PubMed...
    30. Kouloulias V, Plataniotis G, Kouvaris J, et al. Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial. Am J Clin Oncol. 2005;28:91-9. doi.org/10.1097/01.coc.0000139939.60056.42. Go to original source... Go to PubMed...
    31. Ott OJ, Schmidt M, Semrau S, et al. Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus. Strahlenther Onkol. 2019;195(7):607-614. English. doi: 10.1007/s00066-018-1396-x. Go to original source... Go to PubMed...
    32. Kapp KS, Kapp DS, Stuecklschweiger G, et al. Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study. Int J Radiat Oncol Biol Phys. 1994;28(1):189-199. doi: 10.1016/0360-3016(94)90157-0. Go to original source... Go to PubMed...
    33. Evesque L, Benezery K, Follana P, et al. Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience. Dis Colon Rectum. 2017;60(8):785-791. doi: 10.1097/DCR.0000000000000827. Go to original source... Go to PubMed...
    34. Sclafani F, Hesselberg G, Thompson SR, et al. Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review. J Surg Oncol. 2019;119(4):489-496. doi: 10.1002/jso.25320. Go to original source... Go to PubMed...
    35. Eng C, Chang GJ, You YN, et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014;5(22):11133-11142. doi: 10.18632/oncotarget.2563. Go to original source... Go to PubMed...
    36. Rao S, Sclafani F, Eng C, et al. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. J Clin Oncol. 2020;38(22):2510-2518. doi: 10.1200/JCO.19.03266. Go to original source... Go to PubMed...
    37. Kim S, Buecher B, André T, et al. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. BMC Cancer. 2020;20(1):352. doi: 10.1186/s12885-020-06841-1. Go to original source... Go to PubMed...
    38. Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(4):446-453. doi: 10.1016/S1470-2045(17)30104-3. Go to original source... Go to PubMed...
    39. Marabelle A, Cassier PA, Fakih M, et al. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. Lancet Gastroenterol Hepatol. 2022;7(5):446-454. doi: 10.1016/S2468-1253(21)00382-4. Go to original source... Go to PubMed...
    40. Lonardi S, Prete AA, Morano F, et al. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. J Immunother Cancer. 2021;9(11):e002996. doi: 10.1136/jitc-2021-002996. Go to original source... Go to PubMed...
    41. Valery M, Cervantes B, Smolenschi C, et al. Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma. Dig Liver Dis. 2022:S1590-8658(22)00652-1. doi: 10.1016/j.dld.2022.08.026. Go to original source... Go to PubMed...
    42. Kim S, Meurisse A, Spehner L, et al. Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma. Ther Adv Med Oncol. 2020;12:1758835920975356. doi: 10.1177/1758835920975356. Go to original source... Go to PubMed...
    43. Rao S, Anandappa G, Capdevila J, et al. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open. 2022;7(4):100529. doi: 10.1016/j.esmoop.2022.100529. Go to original source... Go to PubMed...
    44. Marcellusi A, Mennini FS, Sciattella P, et al. Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data. Eur J Health Econ. 2021;22(9):1371-1379. doi: 10.1007/s10198-021-01317-w. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.